Q: Magazine Issue 9 Feb. 2022 | Page 20

IVIG vs dual therapy
IVIG alone IVIG + infliximab
Required additional therapy
65 % 31 %
Developed left ventricle dysfunction
20 % 4 %
CRP fall at 24 hours
0 %-46 %
CRP fall at 48 hours
-5 %-70 %
Median length of stay
3.3 days 1.8 days
In April of 2020, healthcare
But there are established
“ We needed to adapt,”
Dr. Jone.“ That’ s not
systems around the world
courses of treatment. As in
says Dr. Jone.
good. Some will get a kidney
faced a steep and urgent learning curve: COVID-19 was spreading rapidly, and much about it remained unknown.
Some of the most pressing questions in pediatrics revolved around MIS-C, a severe complication that, while rare, came with some familiar hallmarks— at least to those who knew what to look for.
“ Rash, red eyes, red lips, diarrhea, common things we see in Kawasaki disease,” says Dr. Jone.“ Both are a hyperimmune response to trying to fight infection.”
Kawasaki disease, patients with MIS-C responded to intravenous immunoglobin, or IVIG, a blood product containing thousands of antibodies. Drs. Jone and Dominguez, who’ d run a Children’ s Colorado Kawasaki Clinic together since 2011, started doing MIS-C rounds in spring of 2020, bringing together the infectious disease and cardiology teams to talk through each case every day at 9 a. m.
In many cases, they found, IVIG wasn’ t enough.
CATCHING IT EARLY
By fall of 2020, it was clear that, when it came to MIS-C, time was of the essence.
“ Patients with MIS-C have higher levels of systemic inflammation and more often decompensate,” says Christina Osborne, MD,“ which puts them at risk for requiring admission to intensive care.”
“ They can get myocarditis and very low blood pressure. The heart function goes down, the coronary arteries dilate,” adds
or liver disorder, their blood pressure gets so low. Some go into shock.”
Dr. Osborne, a former fellow in pediatric infectious disease and current fellow in critical care with a research interest in coronaviruses, took on the task of creating a protocol for identifying MIS-C early, with input from infectious disease, hospital medicine, critical care, cardiology, rheumatology and emergency medicine. The protocol combined recommendations from the Centers for Disease Control
Continued on the following page
11